Novel 5-HT6 receptor antagonists/D2 receptor partial agonists targeting behavioral and psychological symptoms of dementia

European Journal of Medicinal Chemistry

Volumn 92, Issue , 2015, Pages 221-235

  Kołaczkowski, Marcin ^a,b   Marcinkowska, Monika ^b   Bucki, Adam ^b   ͆niecikowska, Joanna ^b   Pawłowski, Maciej ^b   Kazek, Grzegorz ^b   Siwek, Agata ^b   Jastrzębska Więsek, Magdalena ^b   Partyka, Anna ^b   Wasik, Anna ^b   Wesołowska, Anna ^b   Mierzejewski, Paweł ^c   Bienkowski, Przemyslaw ^c  

^a Adamed Ltd ^*  (Poland)

^b JAGIELLONIAN UNIVERSITY MEDICAL COLLEGE   (Poland)

^c INSTITUTE OF PSYCHIATRY AND NEUROLOGY   (Poland)

Author keywords

5 HT6R antagonist; BPSD; D2R partial agonist; Dementia; Designed multiple ligand (DML)

Indexed keywords

2 [3 [4 [1 (PHENYLSULFONYL) 1H INDOL 4 YL]PIPERAZIN 1 YL]PROPOXY]BENZAMIDE; 5 CHLORO N [4 METHOXY 3 (1 PIPERAZINYL)PHENYL] 3 METHYL 2 BENZOTHIOPHENESULFONAMIDE; APOMORPHINE; ARIPIPRAZOLE; CHLORPROMAZINE; DOPAMINE 2 RECEPTOR; DOPAMINE 2 RECEPTOR STIMULATING AGENT; HALOPERIDOL; INDOLE DERIVATIVE; METITEPINE; POTASSIUM CHANNEL HERG; SEROTONIN 6 ANTAGONIST; SEROTONIN 6 RECEPTOR; UNCLASSIFIED DRUG; 2-PROPOXYBENZENEAMIDE; 4-(PIPERAZIN-1-YL)-1H-INDOLE; 7-BUTOXY-3,4-DIHYDROQUINOLOIN-2(1H)-ONE; BENZAMIDE DERIVATIVE; LIGAND; PIPERAZINE DERIVATIVE; QUINOLONE DERIVATIVE; SEROTONIN RECEPTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIDEPRESSANT ACTIVITY; ARTICLE; CONTROLLED STUDY; DEMENTIA; HUMAN; HUMAN CELL; IN VITRO STUDY; INSTRUMENTAL CONDITIONING; MALE; NONHUMAN; PHARMACOPHORE; RAT; TRANQUILIZING ACTIVITY; AGONISTS; ANIMAL; CHEMICAL STRUCTURE; CHEMISTRY; DOSE RESPONSE; METABOLISM; PARTIAL AGONISM; PSYCHOLOGY; STRUCTURE ACTIVITY RELATION; SWIMMING; SYNTHESIS; WISTAR RAT;

ANIMALS; BENZAMIDES; DEMENTIA; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG PARTIAL AGONISM; HUMANS; INDOLES; LIGANDS; MALE; MODELS, MOLECULAR; MOLECULAR STRUCTURE; PIPERAZINES; QUINOLONES; RATS; RATS, WISTAR; RECEPTORS, DOPAMINE D2; RECEPTORS, SEROTONIN; STRUCTURE-ACTIVITY RELATIONSHIP; SWIMMING;

EID: 84928941584     PISSN: 02235234     EISSN: 17683254     Source Type: Journal    
DOI: 10.1016/j.ejmech.2014.12.045     Document Type: Article

References (59)

1. B.J. Sadock, V.A. Sadock, Kaplan & Sadock's Concise Textbook of Clinical Psychiatry, Lippincott Williams & Wilkins, 2008.
2. M. Prince, J. Jackson, World Alzheimer Report 2009, Alzheimers Dis. Int., 2009, p. 38. http://www.alz.co.uk/research/worldereporte2009 (accessed 11.03.12.).
3. M. Petrovic, C. Hurt, D. Collins, A. Burns, V. Camus, R. Liperoti, et al., Clustering of behavioural and psychological symptoms in dementia (BPSD): a European Alzheimer's disease consortium (EADC) study, Acta Clin. Belg. 62 (2007) 426-432, http://dx.doi.org/10.1179/acb.2007.062.
4. A.V. Rayner, J.G. O'Brien, B. Schoenbachler, B. Shoenbachler, Behavior disorders of dementia: recognition and treatment, Am. Fam. Physician 73 (2006) 647-652.
5. A. Gustavsson, M. Svensson, F. Jacobi, C. Allgulander, J. Alonso, E. Beghi, et al., Cost of disorders of the brain in Europe 2010, Eur. Neuropsychopharmacol. 21 (2011) 718-779, http://dx.doi.org/10.1016/j.euroneuro.2011.08.008.
6. E.C. Hersch, S. Falzgraf, Management of the behavioral and psychological symptoms of dementia, Clin. Interv. Aging 2 (2007) 611-621.
7. R. Liperoti, C. Pedone, A. Corsonello, Antipsychotics for the treatment of behavioral and psychological symptoms of dementia (BPSD), Curr. Neuropharmacol. 6 (2008) 117-124, http://dx.doi.org/10.2174/157015908784533860.
8. D.V. Jeste, D. Blazer, D. Casey, T. Meeks, C. Salzman, L. Schneider, et al., ACNP White paper: update on use of antipsychotic drugs in elderly persons with dementia, Neuropsychopharmacol. 33 (2008) 957-970, http://dx.doi.org/10.1038/sj.npp.1301492.
9. U.S. Food and Drug Administration, Public Health Advisory: Deaths with Antipsychotics in Elderly Patients with Behavioral Disturbances, Center for Drug Evaluation and Research, Rockville, MD, 2005. Available at: www.fda.gov/Drugs/DrugSafety (accessed 28.11.13.).
10. U.S. Food and Drug Administration, Information on Conventional Antipsychotics, Center for Drug Evaluation and Research, Rockville, MD, 2008. Available at: www.fda.gov/Drugs/DrugSafety (accessed 28.11.13.).
11. M.L. Woolley, C.A. Marsden, K.C.F. Fone, 5-ht6 receptors, Curr. Drug Targets CNS Neurol. Disord. 3 (2004) 59-79, http://dx.doi.org/10.2174/1568007043482561.
12. B. Benhamü, M. Martín-Fontecha, H. Vazquez-Villa, L. Pardo, M.L. Lopez-Rodríguez, Serotonin 5-HT6 receptor antagonists for the treatment of cognitive deficiency in Alzheimer's disease, J. Med. Chem. 57 (2014) 7160-7181, http://dx.doi.org/10.1021/jm5003952.
13. G. Maher-Edwards, M. Zvartau-Hind, A.J. Hunter, M. Gold, G. Hopton, G. Jacobs, et al., Double-blind, controlled phase II study of a 5-HT6 receptor antagonist, SB-742457, in Alzheimer's disease, Curr. Alzheimer Res. 7 (2010) 374-385, http://dx.doi.org/10.2174/156720510791383831.
14. H. Lundbeck, A/S, Lundbeck's Lu AE58054 meets primary endpoint in large placebo-controlled clinical proof of concept study in people with Alzheimer's disease, Corporate Release 472 (2012) 1-4. http://investor.lundbeck.com/releasedetail.cfm?ReleaseID=677436 (accessed 23.10.12.).
15. A. Wesolowska, Potential role of the 5-HT6 receptor in depression and anxiety: an overview of preclinical data, Pharmacol. Rep. P.R. 62 (2010) 564-577.
16. R. Morphy, Z. Rankovic, Designed multiple ligands. An emerging drug discovery paradigm, J. Med. Chem. 48 (2005) 6523-6543, http://dx.doi.org/10.1021/jm058225d.
17. J.L. Medina-Franco, M.A. Giulianotti, G.S. Welmaker, R.A. Houghten, Shifting from the single to the multitarget paradigm in drug discovery, Drug Discov. Today 18 (2013) 495-501, http://dx.doi.org/10.1016/j.drudis.2013.01.008.
18. D.H. Kim, M.J. Maneen, S.M. Stahl, Building a better antipsychotic: receptor targets for the treatment of multiple symptom dimensions of schizophrenia, Neurother. J. Am. Soc. Exp. Neurother. 6 (2009) 78-85, http://dx.doi.org/10.1016/j.nurt.2008.10.020.
19. Z. Liu, J. Zhang, A. Zhang, Design of multivalent ligand targeting G-proteincoupled receptors, Curr. Pharm. Des. 15 (2009) 682-718, http://dx.doi.org/10.2174/138161209787315639.
20. S.M. Stahl, Do dopamine partial agonists have partial efficacy as antipsychotics? CNS Spectr. 13 (2008) 279-282.
21. A. Zhang, J.L. Neumeyer, R.J. Baldessarini, Recent progress in development of dopamine receptor subtype-selective Agents: potential therapeutics for neurological and psychiatric disorders, Chem. Rev. 107 (2007) 274-302, http://dx.doi.org/10.1021/cr050263h.
22. N. Ye, J.L. Neumeyer, R.J. Baldessarini, X. Zhen, A. Zhang, Update 1 of: recent progress in development of dopamine receptor subtype-selective agents: potential therapeutics for neurological and psychiatric disorders, Chem. Rev. 113 (2013) PR123-PR178, http://dx.doi.org/10.1021/cr300113a.
23. S. Leucht, A. Cipriani, L. Spineli, D. Mavridis, D. Orey, F. Richter, et al., Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis, Lancet 382 (2013) 951-962, http://dx.doi.org/10.1016/S0140-6736(13)60733-3.
24. Otsuka Pharmaceutical Co, Ltd, Announces Results from a Phase 2 Study of Investigational Product OPC-34712 as Adjunctive Therapy in Adults with Major Depressive Disorder, 2011. http://www.businesswire.com/news/home/20110515005031/en/OtsukaePharmaceuticaleLtd. eAnnounceseResultsePhasee2#.U75s5LHEfHg (accessed 16.02.12.).
25. M. Kolaczkowski, P. Mierzejewski, P. Bienkowski, A. Wesolowska, A. Newman-Tancredi, Antipsychotic, antidepressant, and cognitive-impairment properties of antipsychotics: rat profile and implications for behavioral and psychological symptoms of dementia, Naunyn. Schmiedeb. Arch. Pharmacol. 387 (2014) 545-557, http://dx.doi.org/10.1007/s00210-014-0966-4.
26. M. Kolaczkowski, P. Mierzejewski, P. Bienkowski, A. Wesolowska, A. Newman-Tancredi, ADN-1184 a monoaminergic ligand with 5-HT6/7 receptor antagonist activity: pharmacological profile and potential therapeutic utility, Br. J. Pharmacol. 171 (2014) 973-984, http://dx.doi.org/10.1111/bph.12509.
27. M. Kolaczkowski, M. Marcinkowska, A. Bucki, M. Pawlowski, K. Mitka, J. Jaskowska, et al., Novel arylsulfonamide derivatives with 5-HT6/5-HT7 receptor antagonism targeting behavioral and psychological symptoms of dementia, J. Med. Chem. 57 (2014) 4543-4557, http://dx.doi.org/10.1021/jm401895u.
28. N. Krogsgaard-Larsen, A.A. Jensen, T.J. Schrøder, C.T. Christoffersen, J. Kehler, Novel aza-analogous ergoline derived scaffolds as potent serotonin 5-HT6 and dopamine D2 receptor ligands, J. Med. Chem. 57 (2014) 5823-5828, http://dx.doi.org/10.1021/jm5003759.
29. M. Kolaczkowski, A. Bucki, M. Feder, M. Pawlowski, Ligand-optimized homology models of D1 and D2 dopamine receptors: application for virtual screening, J. Chem. Inf. Model 53 (2013) 638-648, http://dx.doi.org/10.1021/ci300413h.
30. C.D. Strader, I.S. Sigal, M.R. Candelore, E. Rands, W.S. Hill, R.A. Dixon, Conserved aspartic acid residues 79 and 113 of the beta-adrenergic receptor have different roles in receptor function, J. Biol. Chem. 263 (1988) 10267-10271.
31. M.R. Braden, J.C. Parrish, J.C. Naylor, D.E. Nichols, Molecular interaction of serotonin 5-HT2A receptor residues Phe339(6.51) and Phe340(6.52) with superpotent n-benzyl phenethylamine agonists, Mol. Pharmacol. 70 (2006) 1956-1964, http://dx.doi.org/10.1124/mol.106.028720.
32. D.C. Cole, J.W. Ellingboe, W.J. Lennox, H. Mazandarani, D.L. Smith, J.R. Stock, et al., N1-arylsulfonyl-3-(1,2,3,6-tetrahydropyridin-4-yl)-1H-indole derivatives are potent and selective 5-HT6 receptor antagonists, Bioorg. Med. Chem. Lett. 15 (2005) 379-383, http://dx.doi.org/10.1016/j.bmcl.2004.10.064.
33. R. Depoortere, A.L. Auclair, L. Bardin, L. Bruins Slot, M.S. Kleven, F. Colpaert, et al., F15063, a compound with D2/D3 antagonist, 5-HT 1A agonist and D4 partial agonist properties. III. Activity in models of cognition and negative symptoms, Br. J. Pharmacol. 151 (2007) 266-277, http://dx.doi.org/10.1038/sj.bjp.0707160.
34. P. Szot, S.S. White, J.L. Greenup, J.B. Leverenz, E.R. Peskind, M.A. Raskind, Compensatory changes in the noradrenergic nervous system in the locus ceruleus and hippocampus of postmortem subjects with Alzheimer's disease and dementia with Lewy bodies, J. Neurosci. Off. J. Soc. Neurosci. 26 (2006) 467-478, http://dx.doi.org/10.1523/JNEUROSCI.4265-05.2006.
35. L.Y. Wang, J.B. Shofer, K. Rohde, K.L. Hart, D.J. Hoff, Y.H. McFall, et al., Prazosin for the treatment of behavioral symptoms in patients with Alzheimer disease with agitation and aggression, Am. J. Geriatr. Psychiatry 17 (2009) 744-751, http://dx.doi.org/10.1097/JGP.0b013-3181ab8c61.
36. C. Routledge, S.M. Bromidge, S.F. Moss, G.W. Price, W. Hirst, H. Newman, et al., Characterization of SB-271046: a potent, selective and orally active 5-HT(6) receptor antagonist, Br. J. Pharmacol. 130 (2000) 1606-1612, http://dx.doi.org/10.1038/sj.bjp.0703457.
37. A.F. Schatzberg, C.B. Nemeroff, Textbook of Psychopharmacology, fourth ed., American Psychiatric Publishing, Inc., Washington, 2009.
38. P. Mierzejewski, M. Olczak, A. Rogowski, W. Kostowski, J. Samochowiec, M. Filip, et al., Effects of cycloheximide on extinction in an appetitively motivated operant conditioning task depend on re-exposure duration, Neurosci. Lett. 441 (2008) 307-310, http://dx.doi.org/10.1016/j.neulet.2008.06.047.
39. K. Radwanska, E. Wrobel, A. Korkosz, A. Rogowski, W. Kostowski, P. Bienkowski, et al., Alcohol relapse induced by discrete cues activates components of AP-1 transcription factor and ERK pathway in the rat basolateral and central amygdala, Neuropsychopharmacol. 33 (2008) 1835-1846, http://dx.doi.org/10.1038/sj.npp.1301567.
40. E.Y.T. Chien, W. Liu, Q. Zhao, V. Katritch, G.W. Han, M.A. Hanson, et al., Structure of the human dopamine D3 receptor in complex with a D2/D3 selective antagonist, Science 330 (2010) 1091-1095, http://dx.doi.org/10.1126/science.1197410.
41. V. Cherezov, D.M. Rosenbaum, M.A. Hanson, S.G.F. Rasmussen, F.S. Thian, T.S. Kobilka, et al., High-resolution crystal structure of an engineered human beta2-adrenergic G protein-coupled receptor, Science 318 (2007) 1258-1265, http://dx.doi.org/10.1126/science.1150577.
42. E. Jain, A. Bairoch, S. Duvaud, I. Phan, N. Redaschi, B.E. Suzek, et al., Infrastructure for the life sciences: design and implementation of the UniProt website, BMC Bioinform. 10 (2009) 136, http://dx.doi.org/10.1186/1471-2105-10-136.
43. M.A. Kurowski, J.M. Bujnicki, GeneSilico protein structure prediction metaserver, Nucleic Acids Res. 31 (2003) 3305-3307, http://dx.doi.org/10.1093/nar/gkg557.
44. K. Arnold, L. Bordoli, J. Kopp, T. Schwede, The SWISS-MODEL workspace: a web-based environment for protein structure homology modelling, Bioinforma. Oxf. Engl. 22 (2006) 195-201, http://dx.doi.org/10.1093/bioinformatics/bti770.
45. N. Guex, M.C. Peitsch, SWISS-MODEL and the Swiss-PdbViewer: an environment for comparative protein modeling, Electrophoresis 18 (1997) 2714-2723, http://dx.doi.org/10.1002/elps.1150181505.
46. T. Schwede, J. Kopp, N. Guex, M.C. Peitsch, SWISS-MODEL: an automated protein homology-modeling server, Nucleic Acids Res. 31 (2003) 3381-3385, http://dx.doi.org/10.1093/nar/gkg520.
47. G.M. Sastry, M. Adzhigirey, T. Day, R. Annabhimoju, W. Sherman, Protein and ligand preparation: parameters, protocols, and influence on virtual screening enrichments, J. Comput. Aided Mol. Des. 27 (2013) 221-234, http://dx.doi.org/10.1007/s10822-013-9644-8.
48. W. Sherman, H.S. Beard, R. Farid, Use of an induced fit receptor structure in virtual screening, Chem. Biol. Drug Des. 67 (2006) 83-84, http://dx.doi.org/10.1111/j.1747-0285.2005.00327.x.
49. W. Sherman, T. Day, M.P. Jacobson, R.A. Friesner, R. Farid, Novel procedure for modeling ligand/receptor induced fit effects, J. Med. Chem. 49 (2006) 534-553, http://dx.doi.org/10.1021/jm050540c.
50. N.K. Salam, R. Nuti, W. Sherman, Novel method for generating structure-based pharmacophores using energetic analysis, J. Chem. Inf. Model 49 (2009) 2356-2368, http://dx.doi.org/10.1021/ci900212v.
51. K. Loving, N.K. Salam, W. Sherman, Energetic analysis of fragment docking and application to structure-based pharmacophore hypothesis generation, J. Comput. Aided Mol. Des. 23 (2009) 541-554, http://dx.doi.org/10.1007/s10822-009-9268-1.
52. R.D. Porsolt, G. Anton, N. Blavet, M. Jalfre, Behavioural despair in rats: a new model sensitive to antidepressant treatments, Eur. J. Pharmacol. 47 (1978) 379-391.
53. W. Kostowski, W. Dyr, P. Krzascik, T. Järbe, T. Archer, 5-Hydroxytryptamine1A receptor agonists in animal models of depression and anxiety, Pharmacol. Toxicol. 71 (1992) 24-30.
54. A. Plaznik, W. Danysz, W. Kostowski, A stimulatory effect of intraaccumbens injections of noradrenaline on the behavior of rats in the forced swim test,, Psychopharmacol. (Berl.) 87 (1985) 119-123.
55. N.B. Eddy, D. Leimbach, Synthetic analgesics. II. Dithienylbutenyl-and dithienylbutylamines, J. Pharmacol. Exp. Ther. 107 (1953) 385-393.
56. H. Sienkiewicz-Jarosz, A.I. Czlonkowska, M. Siemiatkowski, P. Maciejak, J. Szyndler, A. Plaznik, The effects of physostigmine and cholinergic receptor ligands on novelty-induced neophobia, J. Neural Transm. Vienna Austria 1996 107 (2000) 1403-1412.
57. H. Sienkiewicz-Jarosz, P. Maciejak, P. Krzascik, A.I. Czlonkowska, J. Szyndler, A. Bidzinski, et al., The effects of central administration of physostigmine in two models of anxiety, Pharmacol. Biochem. Behav. 75 (2003) 491-496, http://dx.doi.org/10.1016/S0091-3057(03)00141-2.
58. A. Scinska, L. Swiecicki, I. Korkosz, P. Mierzejewski, M. Kolaczkowski, Immobility in the tail suspension test predicts quinine but not saccharin intake in mice, Neurosci. Lett. 461 (2009) 285-288, http://dx.doi.org/10.1016/j.neulet.2009.06.046.
59. R. Murray, K.A. Boss-Williams, J.M. Weiss, Effects of chronic mild stress on rats selectively bred for behavior related to bipolar disorder and depression, Physiol. Behav. 119 (2013) 115-129, http://dx.doi.org/10.1016/j.physbeh.2013.05.042.